1. Peptides

Teriparatide (Synonyms: PTH 1-34; hPTH (1-34); Human parathyroid hormone-(1-34))

Cat. No.: HY-P0059 Purity: 99.92%
SDS Handling Instructions

Teriparatide is a PHT agonist, binds to the receptor for PHT present in bone and stimulates the G-protein-related production of cyclic monophosphate.

For research use only. We do not sell to patients.
Teriparatide Chemical Structure

Teriparatide Chemical Structure

CAS No. : 52232-67-4

Size Price Stock Quantity
1 mg $100 In-stock
5 mg $150 In-stock
10 mg $210 In-stock
50 mg $420 In-stock
100 mg $620 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Technical Information

  • Purity & Documentation

  • References

Description

Teriparatide is a PHT agonist, binds to the receptor for PHT present in bone and stimulates the G-protein-related production of cyclic monophosphate. THA recombinant 1-34 amino acid segment THA. In vitro: THA may also stimulate mesenchymal stem cell proliferation and stem cell maturation in the musculoskeletal lineage. PTH(1-34) is able to maintain serum calcium and phosphate levels and to improve quality of life (QOL) with postsurgical hypoparathyroidism with no serious side effects. stimulates modeling- and remodeling-based bone formation through natural homeostatic system.increase the cortical thickness and porosity. In vivo: The adminstration for TPTD is 20 μg/kg (subcutaneously ) TPTD administration increased the BMC, volumetric BMD, and cortical thickness and decreased the pore ratio.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00018447 VA Office of Research and Development Osteoporosis, Post-Menopausal November 1998 Phase 2
NCT00395538 National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) Hypoparathyroidism|DiGeorge Syndrome October 27, 2006 Phase 3
NCT00697463 Columbia University|Eli Lilly and Company Menopause|Fracture|Osteoporosis August 2008 Phase 2|Phase 3
NCT00086619 Massachusetts General Hospital|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Postmenopausal Osteoporosis|Osteoporosis May 2004 Phase 2
NCT00004993 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Osteoporosis August 1999 Phase 2
NCT01293292 Sheffield Teaching Hospitals NHS Foundation Trust Osteoporosis January 2011 Phase 4
NCT00557310 Eli Lilly and Company Osteoporosis, Postmenopausal November 2007 Phase 4
NCT02091492 Medical University of Vienna Osteoporosis, Age-Related|Humeral Fractures June 2014 Phase 3
NCT00131469 Oregon Health and Science University|Eli Lilly and Company|Osteogenesis Imperfecta Foundation|National Institutes of Health (NIH)|National Center for Research Resources (NCRR) Osteogenesis Imperfecta June 2005 Phase 4
NCT01171690 Mayo Clinic Hypoparathyroidism Post-surgical November 2010 Phase 2
NCT01155232 University Health Network, Toronto Osteoporosis November 2004
NCT00347737 Leland Graves III, MD|University of Kansas|University of Kansas Medical Center Osteoporosis June 2006
NCT00532545 Eli Lilly and Company Osteoporosis, Post-Menopausal April 2003 Phase 4
NCT01760798 Postgraduate Institute of Medical Education and Research Osteoporosis January 2012
NCT01705587 University of Pittsburgh|Eli Lilly and Company Osteoporosis|Atypical Femoral Fracture December 2012 Phase 4
NCT02025179 Northwestern University|United States Department of Defense Spinal Cord Injury|Bone Loss|Osteoporosis January 2013 Phase 2
NCT00259298 Eli Lilly and Company Osteoporosis November 2005 Phase 4
NCT01173081 Ohio Orthopedic Center of Excellence|Eli Lilly and Company Fractures July 2010 Phase 4
NCT00532207 Eli Lilly and Company Osteoporosis, Post-Menopausal November 2003 Phase 3
NCT00577863 Eli Lilly and Company Osteoporosis January 2008 Phase 3
NCT01896011 University Health Network, Toronto|The Physicians' Services Incorporated Foundation|Eli Lilly and Company Non Displaced Atypical Femoral Fractures July 2013 Phase 3
NCT01360424 Helsinki University Central Hospital|Eli Lilly and Company Osteoporosis May 2011 Phase 4
NCT01292252 University of California, San Francisco|Eli Lilly and Company Lumbar Spondylosis|Lumbar Spondylolisthesis|Adult Degenerative Lumbar Scoliosis August 2011
NCT00926380 Massachusetts General Hospital|Amgen Osteoporosis June 2009 Phase 2
NCT01440803 Elizabeth Shane|Creighton University|Columbia University Adult Idiopathic Generalized Osteoporosis January 2012 Phase 2
NCT00191321 Eli Lilly and Company Osteoporosis July 2004 Phase 3
NCT03072147 Mike Zuscik|Eli Lilly and Company|University of Rochester|Duke University|Milton S. Hershey Medical Center Knee Osteoarthritis|Cartilage Degeneration May 2017 Phase 2
NCT00594906 University of Rochester|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health (NIH) Pelvic Fracture January 2008
NCT01225055 Thomas J. Schnitzer|Edward Hines Jr. VA Hospital|University of Illinois at Chicago|Northwestern University Spinal Cord Injury|Bone Loss|Osteoporosis October 2010 Phase 2
NCT02023411 Postgraduate Institute of Medical Education and Research Diabetic Neuropathic Arthropathy January 2014 Phase 2
NCT02176382 Massachusetts General Hospital Postmenopausal Osteoporosis August 2014 Phase 4
NCT03002428 Pfenex, Inc Osteoporosis December 2016 Phase 3
NCT02090244 University Hospital, Linkoeping|Medical Research Council of Southeast Sweden Spinal Stenosis August 2012 Phase 4
NCT01011556 Eli Lilly and Company|TransPharma Medical Osteoporosis November 2009 Phase 2
NCT01430104 Eli Lilly and Company Osteoporosis August 2011 Phase 4
NCT01796301 Amgen Postmenopausal Osteoporosis January 31, 2013 Phase 3
NCT00433160 Eli Lilly and Company Osteoporosis January 2007 Phase 3
NCT01400516 Brigham and Women's Hospital|Eli Lilly and Company Rheumatoid Arthritis August 2011 Phase 4
NCT00439244 Novartis Osteoporosis December 2006 Phase 3
NCT00927186 Eli Lilly and Company Osteoporosis, Post-menopausal July 2009 Phase 4
NCT02656810 Pfenex, Inc Osteoporosis December 2015 Phase 1
NCT00191867 Eli Lilly and Company Osteoporosis February 2005 Phase 2
NCT00191802 Eli Lilly and Company Osteoporosis September 2003 Phase 3
NCT01750086 Massachusetts General Hospital Postmenopausal Osteoporosis January 2013 Phase 4
NCT00543218 Eli Lilly and Company Osteoporosis, Post-Menopausal December 2002 Phase 3
NCT01535027 Medical University of Vienna Osteoporosis March 2006 Phase 4
NCT00624481 Nastech Pharmaceutical Company, Inc. Osteopenia|Osteoporosis March 2008 Phase 2
NCT00543023 Eli Lilly and Company Osteoporosis, Post-Menopausal June 2003 Phase 3
NCT00542984 Eli Lilly and Company Osteoporosis, Postmenopausal August 2003 Phase 3
NCT01309399 Health Research, Inc.|Hospital for Special Surgery, New York|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Osteoporosis August 2010
NCT00623974 M.D. Anderson Cancer Center|Eli Lilly and Company Hypocalcemia May 2008 Phase 2
NCT01473589 Eli Lilly and Company Femur Neck Fracture February 2012 Phase 3
NCT00343252 Eli Lilly and Company Osteoporosis, Postmenopausal|Back Pain|Spinal Fracture June 2006 Phase 3
NCT00670501 Eli Lilly and Company Osteoporosis, Postmenopausal August 1996 Phase 3
NCT01473602 Eli Lilly and Company Femur Neck Fracture January 2012 Phase 3
NCT01945788 Bio Sidus SA Postmenopausal Osteoporosis With Pathological Fracture June 2013 Phase 4
NCT00079924 Eli Lilly and Company Postmenopausal Osteoporosis November 2004 Phase 4
NCT01105832 University Hospital, Linkoeping Humeral Fracture April 2010 Phase 4
NCT01753856 Eli Lilly and Company Osteoporosis January 2013 Phase 4
NCT02416271 Eli Lilly and Company Osteoporosis April 2001 Phase 4
NCT03133195 King Chulalongkorn Memorial Hospital Unstable Intertrochanteric Fracture May 17, 2017 Phase 3
NCT00446589 Papageorgiou General Hospital Osteoporosis July 2006 Phase 4
NCT00761332 Eli Lilly and Company Osteoporosis February 2008
NCT00051558 Eli Lilly and Company Osteoporosis November 2002 Phase 3
NCT00191893 Eli Lilly and Company Osteoporosis September 2003 Phase 3
NCT00190944 Eli Lilly and Company Colles' Fracture December 2004 Phase 2
NCT00191425 Eli Lilly and Company Osteoporosis, Postmenopausal August 2002 Phase 4
NCT00035256 Eli Lilly and Company Osteoporosis, Postmenopausal October 2001 Phase 4
NCT02156960 Shinshu University Osteoporosis May 2014 Phase 4
NCT01679080 University of Aarhus Osteogenesis Imperfecta November 2012 Phase 2
NCT00503399 Eli Lilly and Company Osteoporosis July 2007 Phase 3
NCT01063504 University Hospital, Linkoeping Osteoarthritis of the Knee February 2010 Phase 2
NCT01734824 Medical University of Vienna Bone Marrow Oedema Syndrome|High Turnover Bone Disease|Quality of Life May 2012 Phase 4
NCT00535860 TransPharma Medical|Eli Lilly and Company Osteoporosis April 2008 Phase 2
NCT00239629 Eli Lilly and Company Postmenopausal Osteoporosis September 2005 Phase 4
NCT00668941 Helen Hayes Hospital|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Health Research, Inc. Osteoporosis September 2005 Phase 2
NCT01709110 Eli Lilly and Company Postmenopausal Osteoporosis October 2012 Phase 4
NCT00489918 Zosano Pharma Inc. Osteoporosis June 2007 Phase 2
NCT02972424 Helen Hayes Hospital|Hospital for Special Surgery, New York|Weill Medical College of Cornell University Osteoporotic Fractures January 2017 Phase 2
NCT00887354 Eli Lilly and Company Osteoporosis April 2009 Phase 4
NCT00414973 Eli Lilly and Company Osteoporosis December 2006 Phase 3
NCT01604057 Azelon Pharmaceuticals Osteoporosis|Osteopenia November 2011 Phase 2
NCT01166958 University of Wisconsin, Madison Osteoporosis September 2010 Phase 4
NCT01279187 University of Michigan|Eli Lilly and Company Implant February 2011 Phase 2
NCT00754442 University of Maryland Secondary Hyperparathyroidism February 2007
NCT02223416 Gedeon Richter Plc. Healthy Phase 1
NCT01611571 Columbia University|Alliance for Better Bone Health Osteoporosis December 2003 Phase 3
NCT02571140 Entera Bio Ltd. Drug Safety and Bioavailability October 2013 Phase 1
NCT00696644 Eli Lilly and Company Osteoporosis, Postmenopausal|Osteoporosis June 2008
NCT00046137 Eli Lilly and Company Osteoporosis, Postmenopausal Phase 3
NCT01321723 Unigene Laboratories Inc.|GlaxoSmithKline Postmenopausal Osteoporosis February 2011 Phase 2
NCT00393380 The EMMES Corporation|National Heart, Lung, and Blood Institute (NHLBI) Leukemia, Myeloid, Chronic|Anemia, Aplastic|Myelofibrosis|Lymphoma|Hodgkin Disease|Leukemia, Lymphocytic, Chronic|Leukemia, Myelocytic, Acute|Leukemia, Lymphocytic, Acute September 2006 Phase 2
NCT00826228 Thomas J. Schnitzer|Eli Lilly and Company|Shirley Ryan AbilityLab|Northwestern University Osteoporosis|Bone Loss|Spinal Cord Injury June 2009 Phase 4
NCT01343004 Radius Health, Inc. Osteoporosis|Postmenopausal Osteoporosis April 2011 Phase 3
NCT00005006 Helen Hayes Hospital|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Osteoporosis September 1987 Phase 2
NCT02472782 251 Hellenic Air Force & VA General Hospital|Hellenic Osteoporosis Foundation (www.http://heliost.gr/en/) Osteoporosis, Postmenopausal|Osteoporosis, Steroid Induced May 2015
NCT02563353 Odense University Hospital|University of Southern Denmark|Copenhagen University Hospital, Denmark|Hospital of South West Denmark|Sygehus Lillebaelt|OPEN - Odense Patient data Explorative Network|Region of Southern Denmark Osteoporosis November 2015
NCT00759772 Massachusetts General Hospital|Eli Lilly and Company Anorexia Nervosa|Osteoporosis September 2008 Phase 2
NCT00065637 University of California, San Francisco|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Osteopenia|Osteoporosis December 2003 Phase 3
NCT02440581 Hartmut Malluche, MD|Wright State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky Kidney Failure, Chronic July 2015
NCT02304887 Toshihiko Kono|Tomidahama Hospital Osteoporosis January 2006
NCT02202603 Entera Bio Ltd. Drug Safety July 2011 Phase 1
NCT01656629 Johns Hopkins University Low Bone Density August 2012
NCT00471237 GlaxoSmithKline Osteoporosis May 2007 Phase 2
NCT02824718 Assistance Publique - Hôpitaux de Paris|Ministry of Health, France Autosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment June 6, 2017 Phase 2
NCT00542425 Radius Health, Inc. Osteoporosis April 2007 Phase 2
NCT00896532 Amgen Low Bone Mineral Density|Postmenopausal Osteoporosis June 3, 2009 Phase 2
View MoreCollapse
References
Molecular Weight

4117.72

Formula

C₁₈₁H₂₉₁N₅₅O₅₁S₂

CAS No.

52232-67-4

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O: ≥50 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.92%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Teriparatide
Cat. No.:
HY-P0059
Quantity: